Opportunity Information: Apply for CDC RFA GH14 1409
Apply for CDC RFA GH14 1409
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Population based HIV Impact Assessments in Resource Constrained Settings under the Presidents Emergency Plan for AIDS Relief (PEPFAR)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.067 Global AIDS.
- This funding opportunity was created on Mar 20, 2014 and posted on Mar 20, 2014.
- Applicants must submit their applications by May 5, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $125,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $25,000,000.00 in funding.
- The number of recipients for this funding is limited to 2 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Eligible Applicants Eligible applicants that can apply for this funding opportunity are listed below Nonprofit with 501C3 IRS status (other than institution of higher education) Nonprofit without 501C3 IRS status (other than institution of higher education) For profit organizations (other than small business) Small, minority, and women owned businesses Universities Colleges Research institutions Hospitals Community based organizations Faith based organizations Federally recognized or state recognized American Indian/Alaska Native tribal governments American Indian/Alaska native tribally designated organizations Alaska Native health corporations Urban Indian health organizations Tribal epidemiology centers State and local governments or their Bona Fide Agents (this includes the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Marianna Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau) Political subdivisions of States (in consultation with States) Non domestic (non U.S.) entity
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The CDC funding opportunity CDC RFA GH14-1409, titled "Population based HIV Impact Assessments in Resource Constrained Settings under the Presidents Emergency Plan for AIDS Relief (PEPFAR)," was a large-scale discretionary grant program issued as a cooperative agreement to support population-level measurement and program improvement in countries facing constrained health system resources. Its core purpose was to generate credible, actionable evidence on HIV burden and program impact, while also strengthening the systems needed to deliver and monitor HIV prevention, care, and treatment services. In practical terms, the opportunity aimed to help countries and implementing partners move beyond isolated clinic data and instead use broader surveillance and assessment approaches to understand where infections are occurring, who is being reached, and which interventions are working well enough to justify expansion.
A major focus of the announcement was primary prevention of HIV infection. The opportunity emphasized expanding confidential counseling and testing services and ensuring those services are linked to evidence-based behavioral change interventions rather than operating as stand-alone testing campaigns. It also highlighted prevention of mother-to-child transmission (PMTCT) as a priority, recognizing that reducing infant infections requires a full chain of services: identifying pregnant people living with HIV, connecting them to antiretroviral therapy, supporting adherence and retention, and improving follow-up for mothers and infants. The overall prevention intent was to strengthen early identification of HIV and reduce onward transmission by pairing testing with proven prevention strategies and stronger service linkages.
The grant also emphasized improving care and treatment for HIV/AIDS, sexually transmitted infections (STIs), and opportunistic infections, with particular attention to the real-world constraints that limit outcomes in many settings. It called for improving STI management, expanding laboratory diagnostic capacity, and strengthening the ability of clinical programs to diagnose and treat opportunistic infections that commonly complicate HIV disease. Tuberculosis (TB) was singled out as a key intercurrent disease affecting people living with HIV, reflecting the high burden of HIV/TB co-infection in many PEPFAR-supported countries and the need for integrated screening, diagnosis, and treatment approaches. Another explicit component was initiating or expanding programs that provide antiretroviral therapy (ART), which indicates the opportunity was meant not only to measure impact, but also to support implementation improvements that translate assessment findings into better treatment coverage and health outcomes.
A third pillar of the opportunity centered on surveillance, data use, and national program management capacity. The announcement prioritized strengthening countries ability to collect, analyze, and use surveillance data to guide decisions and manage national HIV/AIDS programs more effectively. This included expanding HIV, STI, and TB surveillance activities and reinforcing laboratory systems that support surveillance, diagnosis, treatment, and ongoing disease monitoring. It also referenced HIV screening for blood safety, underscoring that national HIV control efforts depend on reliable laboratory infrastructure and quality systems that protect patients and the broader public. The common thread across these elements is that population-based impact assessments are only as useful as the health information and laboratory systems that support them, and the funding sought to build those systems alongside the assessments.
Another key feature of the funding was an expectation that recipients would develop, validate, and/or evaluate public health programs and methods in ways that directly inform and improve interventions. Rather than treating evaluation as a compliance exercise, the opportunity framed it as a pathway to targeting resources more precisely and improving the effectiveness of prevention, care, and treatment for HIV/AIDS, TB, and opportunistic infections. This includes generating evidence that can help countries decide which intervention packages to scale, how to reach underserved populations, and how to adjust program strategies based on measured outcomes.
From an administrative standpoint, this was a CDC cooperative agreement, meaning recipients would typically work in close collaboration with CDC on technical direction, monitoring, and implementation learning. The total estimated funding was $125,000,000, with an award ceiling of $25,000,000, and the CDC anticipated making two awards. There was no cost-sharing or matching requirement, which reduces the financial barrier for applicants and can be especially important for organizations working in low-resource environments. The opportunity was posted March 20, 2014, with an original and final closing date of May 5, 2014, and it was archived June 4, 2014.
Eligibility was broad and inclusive, spanning nonprofit organizations (with and without 501(c)(3) status), for-profit organizations (other than small businesses), small/minority/women-owned businesses, universities and colleges, research institutions, hospitals, community-based and faith-based organizations, tribal governments and tribal health entities, urban Indian health organizations, tribal epidemiology centers, and state and local governments and their bona fide agents, including U.S. territories and affiliated jurisdictions named in the announcement. Non-U.S. entities were also eligible, which aligns with the global scope of PEPFAR and the practical reality that many high-burden settings are outside the United States. Overall, the eligibility language suggests CDC intended to attract implementers with field presence, laboratories and surveillance expertise, evaluation and research capacity, and strong partnerships with ministries of health and national programs.
For applicants needing help accessing the full announcement, the notice directed inquiries to the CDC Procurement and Grants Office Technical Information Management Section (PGOTIM) at 770-488-2700.
FAQs: CDC RFA GH14-1409 - Population based HIV Impact Assessments in Resource Constrained Settings (PEPFAR)
What is CDC RFA GH14-1409?
CDC RFA GH14-1409 is a CDC cooperative agreement funding opportunity titled "Population based HIV Impact Assessments in Resource Constrained Settings under the Presidents Emergency Plan for AIDS Relief (PEPFAR)." It supported large-scale, population-level measurement and program improvement activities in countries with constrained health system resources.
What was the main purpose of this funding opportunity?
The core purpose was to generate credible, actionable evidence on HIV burden and program impact, while also strengthening the systems needed to deliver and monitor HIV prevention, care, and treatment services. The intent was to help countries and partners move beyond isolated clinic data and use broader surveillance and assessment approaches to understand where infections are occurring, who is being reached, and which interventions are working well enough to expand.
What type of award was this?
This opportunity was issued as a CDC cooperative agreement, meaning recipients were expected to work in close collaboration with CDC on technical direction, monitoring, and implementation learning.
How much funding was available under this opportunity?
The total estimated funding amount was $125,000,000.
What was the maximum award size (award ceiling)?
The award ceiling was $25,000,000.
How many awards did CDC anticipate making?
CDC anticipated making two awards.
Was there a cost-sharing or matching requirement?
No. The opportunity stated there was no cost-sharing or matching requirement.
When was the opportunity posted and when did it close?
The opportunity was posted on March 20, 2014. The original and final closing date was May 5, 2014.
Is this funding opportunity still open?
No. The opportunity was archived on June 4, 2014, and the final closing date was May 5, 2014.
What settings or contexts were targeted by this opportunity?
The funding targeted resource-constrained settings, particularly countries supported under PEPFAR where health system limitations can affect HIV prevention, care, treatment, surveillance, and laboratory capacity.
What were the main programmatic focus areas?
The announcement emphasized three broad pillars: (1) primary prevention of HIV infection, (2) improving care and treatment for HIV/AIDS and related infections and conditions, and (3) strengthening surveillance, data use, laboratory systems, and national program management capacity.
How did the opportunity define or describe primary HIV prevention priorities?
It emphasized expanding confidential counseling and testing services and ensuring testing is linked to evidence-based behavioral change interventions rather than being run as stand-alone testing campaigns. The goal was early identification of HIV and reduced onward transmission by pairing testing with proven prevention strategies and stronger service linkages.
Did the opportunity prioritize prevention of mother-to-child transmission (PMTCT)?
Yes. PMTCT was highlighted as a priority, with a focus on the full chain of services: identifying pregnant people living with HIV, connecting them to antiretroviral therapy, supporting adherence and retention, and improving follow-up for mothers and infants.
What care and treatment improvements were emphasized?
The grant emphasized improving care and treatment for HIV/AIDS, sexually transmitted infections (STIs), and opportunistic infections. It called for improving STI management, expanding laboratory diagnostic capacity, and strengthening clinical programs to diagnose and treat opportunistic infections that complicate HIV disease.
Was tuberculosis (TB) addressed in this opportunity?
Yes. TB was singled out as a key intercurrent disease affecting people living with HIV, reflecting the high burden of HIV/TB co-infection in many PEPFAR-supported countries and the need for integrated screening, diagnosis, and treatment approaches.
Did the opportunity include antiretroviral therapy (ART) programming?
Yes. The announcement explicitly referenced initiating or expanding programs that provide antiretroviral therapy (ART), indicating an intent to support implementation improvements that translate assessment findings into better treatment coverage and outcomes.
What did the opportunity say about surveillance and data use?
A major emphasis was strengthening countries ability to collect, analyze, and use surveillance data to guide decisions and manage national HIV/AIDS programs more effectively. This included expanding HIV, STI, and TB surveillance activities and reinforcing supporting laboratory systems.
How were laboratory systems positioned within the opportunity?
Laboratory systems were framed as essential to both surveillance and service delivery, supporting surveillance, diagnosis, treatment, and ongoing disease monitoring. The announcement also referenced HIV screening for blood safety, underscoring the role of reliable laboratory infrastructure and quality systems in national HIV control.
What is meant by "population based HIV impact assessments" in this announcement?
Within this opportunity, population-based impact assessments referred to broader surveillance and assessment approaches that can measure HIV burden and program impact at the population level, beyond isolated clinic or facility data, to produce evidence that can guide program improvement and resource targeting.
Was evaluation treated as a required reporting activity or as a program improvement tool?
The opportunity framed evaluation as a pathway to targeting resources more precisely and improving the effectiveness of prevention, care, and treatment, rather than as a compliance-only exercise. Recipients were expected to develop, validate, and/or evaluate public health programs and methods that directly inform interventions.
What kinds of decisions or improvements was the evidence expected to support?
The announcement emphasized generating evidence that could help countries decide which intervention packages to scale, how to reach underserved populations, and how to adjust program strategies based on measured outcomes.
Who was eligible to apply?
Eligibility was broad, including nonprofit organizations (with and without 501(c)(3) status), for-profit organizations (other than small businesses), small/minority/women-owned businesses, universities and colleges, research institutions, hospitals, community-based and faith-based organizations, tribal governments and tribal health entities, urban Indian health organizations, tribal epidemiology centers, and state and local governments and their bona fide agents, including U.S. territories and affiliated jurisdictions named in the announcement.
Were non-U.S. entities eligible?
Yes. Non-U.S. entities were eligible, reflecting the global scope of PEPFAR and the reality that many high-burden settings are outside the United States.
What kinds of organizations did CDC appear to be trying to attract?
Based on the eligibility language and program description, CDC appeared to be seeking applicants with field presence, laboratory and surveillance expertise, evaluation and research capacity, and strong partnerships with ministries of health and national programs.
Where could applicants get help accessing the full announcement?
The notice directed inquiries to the CDC Procurement and Grants Office Technical Information Management Section (PGOTIM) at 770-488-2700.
What does it mean that this opportunity was part of PEPFAR?
The announcement described the work as being under the Presidents Emergency Plan for AIDS Relief (PEPFAR), indicating a focus on HIV response in resource-constrained countries where PEPFAR supports prevention, care, treatment, and related systems strengthening.
Browse more opportunities from the same category: Health
Next opportunity: Cultivating Cultures for Ethical STEM
Previous opportunity: HHFKA Demonstration Projects to End Childhood Hunger FY2015
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA GH14 1409
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA GH14 1409) also looked into and applied for these:
| Funding Opportunity |
|---|
| Rural Access to Emergency Devices Grant Program Apply for HRSA 14 129 Funding Number: HRSA 14 129 Agency: Health Resources and Services Administration Category: Health Funding Amount: $150,000 |
| Public Access to Defibrillation Demonstration Project Apply for HRSA 14 130 Funding Number: HRSA 14 130 Agency: Health Resources and Services Administration Category: Health Funding Amount: $150,000 |
| Mali High Impact Health Services II Apply for RFA 688 14 000005 Funding Number: RFA 688 14 000005 Agency: Mali USAID Bamako Category: Health Funding Amount: $45,000,000 |
| Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network Leadership Center (UM2) Apply for RFA AR 14 015 Funding Number: RFA AR 14 015 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network Research Sites (UH2/UH3) Apply for RFA AR 14 016 Funding Number: RFA AR 14 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Modeling Immunity for Biodefense (U19) Apply for RFA AI 14 028 Funding Number: RFA AI 14 028 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| CDCs National Undergraduate Student Program A Public Helath Workplace Experience to Increase Student Interest in Public Health Apply for CDC RFA MN11 110104CONT14 Funding Number: CDC RFA MN11 110104CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Building Capacity and Networks to Address Emerging Infectious Diseases in the Americas Apply for CDC RFA CK13 130102CONT14 Funding Number: CDC RFA CK13 130102CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Leveraging a Recovery Act Resource to Accelerate Research on Neurodevelopment (R01) Apply for RFA MH 15 400 Funding Number: RFA MH 15 400 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Provider Education and Public Awareness about Primary Immunodeficiency Disease Apply for CDC RFA OE12 120303CONT14 Funding Number: CDC RFA OE12 120303CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Targeting Latently Infected Cells Without Reactivation (R01) Apply for RFA AI 14 021 Funding Number: RFA AI 14 021 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Center for HIV, Viral Hepatitis, STD and TB Prevention (NCHHSTP) Apply for CDC RFA PS13 131502CONT14 Funding Number: CDC RFA PS13 131502CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| NIAID Division of Allergy, Immunology and Transplantation Statistical and Clinical Coordinating Center (UM2) Apply for RFA AI 14 016 Funding Number: RFA AI 14 016 Agency: National Institutes of Health Category: Health Funding Amount: $16,500,000 |
| National Environmental Medicine Education and Consultation Project (NEMECP) Apply for CDC RFA TS14 1401 Funding Number: CDC RFA TS14 1401 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Reduce Hepatitis Infections by Treatment and Integrated Prevention Services (Hepatitis TIPS) among Non urban Young Persons Who Inject Drugs Apply for RFA PS 14 004 Funding Number: RFA PS 14 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| National Diabetes Prevention Program Preventing Type 2 Diabetes Among People at High Risk Apply for CDC RFA DP12 121203CONT14 Funding Number: CDC RFA DP12 121203CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| High Impact Neuroscience Research Resource Grants (R24) Apply for RFA NS 14 006 Funding Number: RFA NS 14 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Studies of Mental Illness Not Involving Treatment Development, Efficacy, or Effectiveness Trials (Collaborative R01) Apply for PAR 14 165 Funding Number: PAR 14 165 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Service Area Competition Additional Area (SAC AA) Warrenton, GA Apply for HRSA 14 136 Funding Number: HRSA 14 136 Agency: Health Resources and Services Administration Category: Health Funding Amount: $1,185,045 |
| Biology of Manual Therapies (R21) Apply for PA 14 167 Funding Number: PA 14 167 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA GH14 1409", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.